Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 8897 results

  1. NY-ESO-1 T-cells for treating synovial sarcoma ID1286

    In development Reference number: GID-TA10205 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development Reference number: GID-TA10248 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

    In development Reference number: GID-TA10249 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development Reference number: GID-TA10250 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development Reference number: GID-MT599 Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  7. The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound

    Awaiting development Reference number: GID-MT603 Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  8. Managing common infections - antimicrobial prescribing guidelines

    In development Reference number: GID-NG10050 Expected publication date: TBC

    NICE guideline
    In development

  9. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development

  10. Bipolar disorder: assessment and management (extraordinary review)

    In development Reference number: GID-NG10380 Expected publication date: TBC

    NICE guideline
    In development

  11. Abdominal aortic aneurysm

    Awaiting development Reference number: GID-QS10035 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-DG10038 Expected publication date: TBC

    Diagnostics guidance
    In development